Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid

Clinical Chemistry

Volumn 61, Issue 5, 2015, Pages 734-743

  Le Bastard, Nathalie ^a,b   De Deyn, Peter Paul ^a,c,d   Engelborghs, Sebastiaan ^a,c  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b FUJIREBIO INC   (Japan)

^c Hospital Network Antwerp   (Belgium)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; GLUCOSE; HYPERPHOSPHORYLATED TAU PROTEIN; NITROGEN; POLYPROPYLENE; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANALYTIC METHOD; ARTICLE; BLOOD CELL COUNT; BLOOD STORAGE; CELL FRACTIONATION; CENTRIFUGATION; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONCENTRATION PROCESS; CONTROLLED STUDY; ERYTHROCYTE COUNT; EVIDENCE BASED PRACTICE; FREEZE THAWING; FREEZING; FREEZING DELAY; HUMAN; LEUKOCYTE COUNT; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; ROOM TEMPERATURE;

ALZHEIMER DISEASE; BIOMARKERS; CENTRIFUGATION; FREEZING; HUMANS;

EID: 84928993056     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2014.236679     Document Type: Article

References (29)

1. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014;13:614-29.
2. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 2012;8:65-73.
3. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement 2013;9:251-61.
4. del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med 2012;6:419-30.
5. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 2001;310:173-86.
6. Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, Anckarsater R et al. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int J Alzheimers Dis 2010;2010:986310.
7. Blennow K, Nellgard B. Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology 2004;62:159; author reply 159-60.
8. Tarnaris A, Toma AK, Chapman MD, Petzold A, Keir G, Kitchen ND et al. Rostrocaudal dynamics of CSF biomarkers. Neurochem Res 2011;36:528-32.
9. de Bont JM, Vanderstichele H, Reddingius RE, Pieters R, van Gool SW. Increased total-tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients. Eur J Paediatr Neurol 2008;12:334-41.
10. 181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med 2006;44:1472-80.
11. Schoonenboom NS, Mulder C, Vanderstichele H, Van Elk EJ, Kok A, Van Kamp GJ et al. Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem 2005;51:189-95.
12. Vanderstichele H, De Meyer G, Shapiro F, Engelborghs S, De Deyn PP, Shaw LM et al. Alzheimer's disease biomarkers: from concept to clinical utility. Biomarkers for Early Diagnosis of Alzheimer's Disease. Hauppauge, NY: Nova Science Publishers, 2008:81-122.
13. Sjögren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 2001;47:1776-81.
14. Kaiser E, Schonknecht P, Thomann PA, Hunt A, Schroder J. Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42). Neurosci Lett 2007;417:193-5.
15. Sancesario GM, Esposito Z, Nuccetelli M, Bernardini S, Sorge R, Martorana A et al. Abeta1-42 Detection in CSF of Alzheimer's disease is influenced by temperature: indication of reversible Abeta1-42 aggregation? Exp Neurol 2010;223:371-6.
16. Lachno DR, Romeo MJ, Siemers ER, Vanderstichele H, Coart E, Konrad RJ et al. Validation of ELISA methods for quantification of total tau and phosporylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies. J Alzheimers Dis 2011;26:531-41.
17. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N et al. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 2000;7:245-58.
18. Zimmermann R, Lelental N, Ganslandt O, Maler JM, Kornhuber J, Lewczuk P. Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics. J Alzheimers Dis 2011;25:739-45.
19. Sullivan JT, Grouper S, Walker MT, Parrish TB, McCarthy RJ, Wong CA. Lumbosacral cerebrospinal fluid volume in humans using three-dimensional magnetic resonance imaging. Anesth Analg 2006;103:1306-10.
20. Ramont L, Thoannes H, Volondat A, Chastang F, Millet MC, Maquart FX. Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice. Clin. Chem Lab Med 2005;43:1215-7.
21. Mollenhauer B, El-Agnaf OM, Marcus K, Trenkwalder C, Schlossmacher MG. Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med 2010;4:683-99.
22. You JS, Gelfanova V, Knierman MD, Witzmann FA, Wang M, Hale JE. The impact of blood contamination on the proteome of cerebrospinal fluid. Proteomics 2005;5:290-6.
23. Le Bastard N, Aerts L, Leurs J, Blomme W, De Deyn PP, Engelborghs S. No correlation between time-linked plasma and CSF Abeta levels. Neurochem Int 2009;55:820-5.
24. Hansson SF, Simonsen AH, Zetterberg H, Andersen O, Haghighi S, Fagerberg I et al. Cystatin C in cerebrospinal fluid and multiple sclerosis. Ann Neurol 2007;62:193-6; discussion 205.
25. Perret-Liaudet A, Pelpel M, Tholance Y, Dumont B, Vanderstichele H, Zorzi W et al. Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes. J Alzheimers Dis 2012;31:13-20.
26. Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ. Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 1996;271:32916-22.
27. Koudinov AR, Koudinova NV, Kumar A, Beavis RC, Ghiso J. Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: association with high density lipoproteins. Biochem Biophys Res Commun 1996;223:592-7.
28. Bouwman FH, van der Flier WM, Schoonenboom NS, Van Elk EJ, Kok A, Scheltens P et al. Usefulness of longitudinal measurements of beta-amyloid1-42 in cerebrospinal fluid of patients with various cognitive and neurologic disorders. Clin Chem 2006;52:1604-6.
29. Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H, Van Everbroeck B, Cras P et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 2008;29:1143-59.